Compare IDEXX Laboratories, Inc. (IDXX) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Wipro Limited — how do they compare? IDEXX Laboratories, Inc. trades at $518.35 (market cap $40.43B), while Wipro Limited trades at $1.71 (market cap $16.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.5× Wipro Limited's market cap, and Wipro Limited pays a 5.19% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Wipro Limited for 41 Days on average.
| IDXX | WIT | |
|---|---|---|
Market Cap | $40.43B | $16.22B |
Volume | 692,164 | 9,028,667 |
Sector | Health | Technology |
52-Week High | $766.68 | $3.06 |
52-Week Low | $504.70 | $1.61 |
Typical Hold Time | 46 Days | 41 Days |
Enterprise Value | $41.32B | $14.33B |
Dividend Yield | — | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
WIT trades at $1.67, down 0.6% on the day, with a bearish technical signal from moving averages and a neutral stance from oscillators. The company reported revenue of $890.88 billion in 2025 with a net income margin of 13.92%, though recent quarters have seen earnings misses against expectations. Recent news highlights Wipro's AI initiatives boosting productivity and new cybersecurity partnerships.
The outlook is mixed; valuation ratios like a P/E of 12.78 appear reasonable, but analyst consensus is cautious with only 19% buy ratings. Key risks include competitive pressures and macroeconomic uncertainty affecting tech spending. Upside hinges on execution of AI strategies and reversing earnings misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
